This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Sign In   |   Register
The EAS-FH Studies Collaboration (FHSC)

A global call to action on FH

To find details of the National Lead Investigators and central contributing clinic for your country, go to the contact list >>

 

EAS FHSC Mission Statement

The mission of the EAS-FHSC is to empower the medical & global community to seek changes in their respective countries or organizations regarding how Familial Hypercholesterolaemia (FH) is detected and managed, with a view to promoting early diagnosis and more effective treatment of this condition. Through international collaboration of stakeholders EAS FHSC generates large scale robust data on how FH is detected, managed and the clinical consequences of current practice on outcomes.

EAS FHSC initiative

Familial Hypercholesterolaemia (FH) represents a major global health problem because, despite being very common, it is widely underdiagnosed, undertreated and, as a result often fatal. The consequences of FH in the form of premature atherosclerosis and cardiovascular events are potentially preventable, but require effective initiatives and policies to address the current issues and reduce the burden of disease.

To address these issues, EAS FH Studies Collaboration (FHSC) has since 2015 collected data from FH investigators from all over the world. The data is pooled, harmonised and analysed to give the investigators a better understanding of FH. EAS FHSC raises awareness of the disease and encourages the development of programmes, initiatives and policies specifically focused on FH, by joining efforts from healthcare providers, patient organizations, policy makers and the entire medical community. A "Call to Action" published in Atherosclerosis at the outset of the project, provides a framework for the extensive work now being undertaken to reduce the impact of FH and the global burden of the disease. 1

EAS FHSC objectives

By establishing the first global Registry of patients with FH, to:

  1. Generate robust information to accurately and reliably investigate the burden of both homozygous and heterozygous FH, how FH is detected and managed, and the clinical consequences of current practices on delivery of care and outcomes.
  2. Disseminate the information gained from the registry to an international audience including physicians, other healthcare professionals, policy-makers and patient organizations.
  3. Consolidate a network of investigators interested in FH, through which collaborative research and networking on FH can be conducted on a large-scale.

A Methods paper was published in Atherosclerosis in 2016, describing the rationale, the design and the methods of the EAS-FHSC project and registry.2

About the EAS FHSC Network

EAS-FHSC is a global initiative led by Prof Kausik Ray (Imperial College London, UK) and an executive committee comprising Prof Alberico L. Catapano (Italy); Dr. Tomas Freiberger (Czech Republic); Prof John Kastelein, Prof G.Kees Hovingh (Netherlands); Prof Pedro Mata (Spain); Dr Handrean Soran (UK); Prof Gerald Watts (Australia); Prof Frederick Raal (South Africa) and Prof Raul Santos (Brazil).

The Coordinating Centre for the EAS FHSC is based at the Imperial Centre for Cardiovascular Disease Prevention (ICCP), School of Public Health, Imperial College London, UK.

To ensure smooth operations within the network, the EAS FHSC collaboration is supported by a number of FH Lead Investigators for their respective countries. Currently, ca. 70 countries and more than 80 Lead investigators are involved. An overview of the current situation related to FH in the involved country has been presented in the FHSC overview article, the first global survey on FH status, published last year in Atherosclerosis.3, 4

More recently, presentations of analyses of the registry data have been made at a late-breaking science session at ESC 2020 Paris, while the publication of the first analyses is currently in preparation. These and subsequent analyses will inform scientific discussion about effective global action for early detection of FH, and effective management and treatment of FH patients.

Read the articles

  1.  Vallejo-Vaz, Antonio J. et al. Familial Hypercholesterolaemia: A global call to arms. Atherosclerosis. http://dx.doi.org/10.1016/j.atherosclerosis.2015.09.021
  2. EAS Familial Hypercholesterolaemia Studies Collaboration, Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies CollaborationAtherosclerosis Supplements 2016;22:1-32.
    http://www.atherosclerosis-supplements.com/issue/S1567-5688(16)X0003-7
  3. Overview of the current status of Familial Hypercholesterolaemia care in over 60 countries - the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) (Free text)
  4. Improving FH care - first survey data from EAS FHSC (Commentary on "Overview of the current status of FH care in over 60 countries)
Membership Software Powered by YourMembership  ::  Legal